When a recipient receives a genetically modified cell therapy product after HCT, there is a need to continue to capture both HCT and CT outcomes. As of the Summer 2020 release, CIBMTR implemented new functionality to reduce center reporting burden and redundancies when having to report multiple cell therapy and HCT events for a single patient. This process is known as “combined follow-up”.
All applicable follow-up forms will be aligned under the same event date at the appropriate timepoints (i.e. Forms 2450+4100 or 2100+4100). Custom enabling and disabling of duplicate questions will streamline follow-up reporting when a recipient receives infusions for multiple indications with overlapping time periods.
If a recipient receives a genetically modified cell therapy infusion and then receives an HCT, all future events will have combined follow-up rules applied as applicable.
Refer to the elearning Combined Follow-Up: HCT and Cellular Therapy for more detailed information on reporting rules.
Scenario 1: HCT -> CT
Questions disabled on HCT and CT Forms
| Question | F4100 | F2450 (when TED level HCT) | F2100 (when CRF level HCT) |
|---|---|---|---|
| Subsequent HCT/CT | Disabled | ||
| Best response to CT | Disabled when disease form present | ||
| Relapse | Disabled when disease form present | Disabled when disease form present | Disabled when disease form present |
| GVHD | Disabled | ||
| Initial ANC recovery | Disabled | Disabled | |
| Initial platelet recovery | Disabled | Disabled | |
| Infection Prophylaxis | N/A | Disabled | |
| Infection | Disabled | Disabled | |
| COVID vaccine | Disabled | Disabled | |
| New malignancy | Disabled | Disabled | |
| Disease assessment at time of best response | Disabled when disease form present | ||
| Post-HCT therapy | Disabled when disease form present | ||
| Intervention | Disabled when disease form present | ||
| Current disease status | Disabled when disease form present |
Scenario 2: CT -> HCT
Questions disabled on HCT and CT Forms
| Question | F4100 | F2450 (when TED level HCT) | F2100 (when CRF level HCT) | |
|---|---|---|---|---|
| Subsequent Infusion | Disabled | |||
| Best response to CT | Disabled when disease form present | |||
| Peripheral Blood Count Recovery | Disabled | |||
| Relapse | Disabled when disease form present | Disabled when disease form present | ||
| GVHD | Disabled | |||
| Current hematologic findings | Disabled | |||
| Infection | Disabled | Disabled | ||
| New malignancy | Disabled | Disabled | ||
| Disease assessment at time of best response | Disabled when disease form present | |||
| COVID vaccine | Disabled | Disabled | ||
| Post-HCT therapy | Disabled when disease form present | |||
| Relapse | Disabled when disease form present | Disabled when disease form present | ||
| Intervention | Disabled when disease form present | |||
| Current disease status | Disabled when disease form present | |||
| Pregnancy | Disabled |